Emergent BioSolutions | EBS - Acreedores Comerciales





Acreedores Comerciales Cambio Fecha
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Akebia Therapeutics USD 21.18M 11.1M 2025-12
ALKERMES USD 107.95M 39.95M 2025-12
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
Amarin USD 45.36M 8.64M 2025-12
ANI Pharmaceuticals USD 62.58M 7.21M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Coherus Biosciences USD 9.91M 14.98M 2025-12
Emergent BioSolutions USD 112.2M 500K 2023-12
Exelixis USD 29.62M 4.27M 2025-12
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Heron Therapeutics USD 8.99M 3.02M 2025-12
Ionis Pharmaceuticals USD 14.33M 8.47M 2025-09
Ironwood Pharmaceuticals USD 1.61M 224K 2025-09
Lexicon Pharmaceuticals USD 3.08M 714K 2025-12
Lonza CHF 471M 3M 2024-12
Merck USD 4.15B 102M 2025-09
Moderna USD 317M 50M 2025-12
Myriad Genetics USD 30M 1.8M 2025-12
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Pacira USD 15.15M 2.54M 2025-12
Pfizer USD 5.02B 142M 2025-09
PTC Therapeutics USD 45.49M 8.87M 2025-12
Sanofi EUR 22.93B 927M 2025-12
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
United Therapeutics USD 7.1M 460.9M 2025-12
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12
Xoma USD 2.65M 1.52M 2025-09